Aortech Share Discussion Threads

[nimbo10] 04/6/2020 12:26

Market valuations are based on future expectations not just yearly accounting figures.

Not much expectation is seen with AOR, this is where well researched holders can capitalize as company developments progress and the market catches up.

[greedy rooster] 04/6/2020 12:22

Goes to show enormous upside potential here though.

[ivor hunch] 04/6/2020 12:06

CREO might not be a good direct comparison, but nevertheless the difference in figures is extraordinary. CREO revenue c£13,000 and pre-tax loss £18.6 million with marketcap £275 million: AOR revenue £470,000, loss just £0.6 million, marketcap £17.8 million. You really wonder how the market arrives at such very different valuations based on comparative figures. It's all to do with fashion, perception and presumably promotion by company brokers.

[mustau] 04/6/2020 09:53

Don’t think creo is a comparator, however agree this is ridiculously undervalued.
No value to all achieved by the company over the last year, should be at least 150m presently.

[semper vigilans] 04/6/2020 08:38

As a rough comparison look at CREO - Progress on their product and a market cap of £275m.
Not a buy tip but pointing to AOR being underrated.

[someuwin] 04/6/2020 08:28

...The clues are all there in that last post.

They have a plan. The plan is working. The plan should deliver huge upside to patient investors!

[greedy rooster] 03/6/2020 11:37

Underpins the mockery of the current share price. Take out values have tended to be 300-500m. 'What we have is substantially more disruptive'. Nice to be sat at £18.2m market value.

[bones] 03/6/2020 11:23

Just posted on ProActive website:

[nimbo10] 03/6/2020 10:57

If the design of the valves is truely oustanding and the've "hit it out of the park" the'll be a queue forming soon on acquring into their portfolio.

Is Bill normally reserved? as this is very high praise indeed.

[bones] 03/6/2020 08:53

GR, agree with that.

Plus, crucially, it was indicated that, following the surgical heart valve design freeze, the design teams will be straight on to the TAVR heart valve project which Bill Brown suggested would be following close behind in terms of speed to trials due to them having essentially cracked the code for manufacturing what is designed (the ideal design) rather than designing to the limitations of what it is thought can be made. Exciting indeed.

[greedy rooster] 03/6/2020 08:14

What I took away from the interview is once we reach design freeze on grafts and heart valve, the R&D team will start on a pipeline of new devices, probably those inherited from the RUA acquisition, which will be 'Elasteoned' - this really is turning into a disruptive tech company whose products are already required.

[bones] 30/5/2020 13:25

Chart du jour:


free stock charts from uk.advfn.com

[bones] 29/5/2020 11:30

Speculating ahead (“speculating” being the word so no hanging of hats on it!), once the HV is design frozen and entered into the regulatory bench top trial (I reckon could be on that for close to a year?), might AorTech let interested parties (large OEM’s) have some samples to test themselves (concurrently) in-house, say for a couple of months, to get an idea of its capabilities? That way, they could decide to enter negotiations if their own shorter tests (on the benchtop) give outstanding data. It’s hard to imagine them not thinking that way.

Just having a sample heart valve to hand should not give away any trade secrets or IP and I guess there would be stringent NDA’s signed. The recent RNS did say the prototypes are “available for evaluation” (although it didn’t say by whom).

The other key factor from an industry (and AorTech) perspective will perhaps be the Primary Outcome Measure of the Foldax in-man trial due in early 2021. The hope I believe is that this is positive as it will go a long way to confirming proof of concept of polymer valves.

If AorTech’s superior manufacturing system and heart valve are still developing well by that time, it’s hard to see the majors staying in the traps for much longer. They may all be racing to catch the hare!

Lots of ifs and buts and much ground to cross before that scenario emerges, naturally!

Speculation ends.....

[someuwin] 29/5/2020 08:04

Lots of news due between now and end of July.

[bones] 28/5/2020 21:37

I’m starting to feel sorry for patients who have received the Foldax heart valve....!

[langland] 28/5/2020 20:22

I tend to agree about AOR's announcements generally. There is one message for punters like me and there is another message for the likes of Edwards. Hopefully, the two messages will coincide at some point to give us a buyout of very significant proportions.

[landy90] 28/5/2020 20:13

Like most statements from Aortech there are subtle messages for the industry in the video.The message about the heart valve having moved away from designing what can be made to making what can be designed sets them apart from Foldax who are still copying the old method of dip casting that the industry worries about.

[bigwig] 28/5/2020 17:19

wow - yes indeed, I've also been doing my real job this afternoon, so very pleased with this.

[langland] 28/5/2020 16:32

Nice to find this higher after being out for a few hours. Mind you, I never doubted it of course...lol

[herschel k] 28/5/2020 16:29

agreed bones - great call that lol

[bones] 28/5/2020 16:22

langland 28 May '20 - 10:49 - 3549 of 3570(premium)

The gap has been closed at 105 so the price can start moving up again now!


Call of the week! 105p at 10.49am; 116.5p at 16.22pm

[bones] 28/5/2020 16:11

Must be some delayed larger trades to be declared at some point.

[bones] 28/5/2020 16:05

What’s the funny business with those £100 share parcels going through every minute?!

[herschel k] 28/5/2020 16:04

How much value could there be in gamechanging heart valve tech I wonder.......Edwards Q1 2020 results should inform us a bit.......oh yeah, despite Covid impacts, sales of $742 million......(so annual, assuming no further growth and Covid impacts remain (which they won't), close to $3bn)AOR market cap is just £18mLet those numbers sink in.......